Author: Michelle Dryden

Categories
Art & Life Business Culture Healthcare Lifestyle Science

IEEE EMBS welcomes Professor He (Helen) Huang as Editor-in-Chief of TNSRE Journal

PISCATAWAY, N.J. — (BUSINESS WIRE) — IEEE, the world’s largest technical professional organization dedicated to advancing technology for humanity, and the IEEE Engineering in Medicine and Biology Society (EMBS), on Friday announced the incoming appointment of Professor He (Helen) Huang as editor-in-chief of IEEE Transactions on Neural Systems and Rehabilitation Engineering (TNSRE). Her duties will commence on Jan. 1, 2024.

Dr. Huang’s research focuses on neural-machine interfaces, prosthetic and exoskeleton control, human-robot interaction, and human movement control. She has more than 15 years of experience as a professor, and currently teaches at the University of North Carolina Chapel Hill and North Carolina State University. She is the Jackson Family Distinguished Professor within the Joint Department of Biomedical Engineering (BME) of both universities, and is the director of the Closed-Loop Engineering for Advanced Rehabilitation core. Dr. Huang also co-founded AVEX Motion, in 2022, a spin-off of her research lab work in wearable robotics and rehabilitation at the Joint Department of BME.

 

“As we look ahead to Dr. Huang’s stewardship of IEEE TNSRE, we anticipate an exciting chapter of growth, innovation, and impactful research,” said Paul Sajda, Ph.D., president of the IEEE EMBS. “Her remarkable achievements throughout the course of her career as a researcher, author, and associate editor give us confidence in her tenure at the journal.”

 

Dr. Huang earned her M.S. and Ph.D. in biomedical engineering from Arizona State University. She has earned numerous accolades, including the Delsys Prize for Innovation in Electromyography, the Mary E. Switzer Fellowship with NIDRR (now NIDILRR), the NSF CAREER Award, the ASA SPES Award, and the ALCOA Foundation Distinguished Engineering Research Award. She is a distinguished fellow of AIMBE, IEEE and a member of many other esteemed organizations.

 

“I aspire to improve the lives of people with disabilities by creating the symbiotic relationship between people with limb loss and robotic prostheses in my own research,” said Dr. Huang. “As editor-in-chief of TNSRE, I want to amplify the voices of my colleagues in the neural systems and rehabilitation engineering fields, and illuminate the importance of this work. I look forward to working with the editors and the team at IEEE TNSRE in accomplishing the missions of the journal and the society, and providing quality, field-leading research to our peers.”

 

About the IEEE Engineering in Medicine and Biology Society

The IEEE Engineering in Medicine and Biology Society (EMBS) is the world’s largest international society of Biomedical Engineers. With more than 9,500 members residing in some 97 countries around the world, it’s a true global connection, providing access to the most fascinating people, practices, information, ideas, opinion and fellowship from one of science’s fastest growing fields: biomedical engineering. From formalized mathematical theory through experimental science, from technological development to practical clinical applications, IEEE EMBS members support scientific, technological, and educational activities as they apply to the concepts and methods of the physical and engineering sciences in biology and medicine. By working together, we can transform and revolutionize the future of medicine and healthcare. For more information about the IEEE EMBS, please visit www.embs.org.

Contacts

Azeem Zeekrya

HDMZ

azeem.zeekrya@hdmz.com
(312) 506-5244

Categories
Business Healthcare International & World Lifestyle Science Technology

Teva to host conference call to discuss third quarter 2023 financial results at 8 a.m. ET on Nov. 8, 2023

TEL AVIV, Israel — (BUSINESS WIRE) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its third quarter 2023 financial results on Wednesday, Nov. 8, 2023, at 7 a.m. ET. Following the release, Teva will conduct a conference call and live webcast, at 8 a.m. ET.

 

In order to participate, please register in advance here to obtain a local or toll-free phone number and your personal pin.

 

A live webcast of the call will be available on Teva’s website at: https://ir.tevapharm.com/Events-and-Presentations

 

Following the conclusion of the call, a replay of the webcast will be available within 24 hours on Teva’s website.

 

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has been developing and producing medicines to improve people’s lives for more than a century. We are a global leader in generic and innovative medicines with a portfolio consisting of over 3,500 products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day and are served by one of the largest and most complex supply chains in the pharmaceutical industry. Along with our established presence in generics, we have significant innovative research and operations supporting our growing portfolio of innovative and biopharmaceutical products. Learn more at www.tevapharm.com.

 

Cautionary Note Regarding Forward-Looking Statements

This document and the conference call, may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully compete in the marketplace; our substantial indebtedness; our business and operations in general including: the impact of global economic conditions and other macroeconomic developments and the governmental and societal responses thereto; compliance, regulatory and litigation matters; other financial and economic risks; and other factors discussed in this press release and in our Annual Report on Form 10-K for the year ended December 31, 2022, including in the sections captioned “Risk Factors.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.

Contacts

IR Contacts
Ran Meir, +1 (267) 468-4475

Yael Ashman, +972 (3) 914 8262

Sanjeev Sharma, +1 (973) 658-2700

 

PR Contacts
Kelley Dougherty, +1 (973) 832-2810

Eden Klein, +972 (3) 906 2645

Categories
Art & Life Business Lifestyle Programs & Events Science

Cornerstone Building Brands celebrates Manufacturing Day 2023

Exterior building solutions company celebrates team member impact and future manufacturing workforce

 

CARY, N.C. — (BUSINESS WIRE) — Cornerstone Building Brands, Inc. “(Cornerstone Building Brands),” the largest manufacturer of exterior building products in North America by sales, announced plans to celebrate National Manufacturing Day (MFG Day) across its North American facilities.

 

Beginning on Friday, and continuing throughout October, the company will host events to honor its nearly 20,000 team members and open its doors to future manufacturing talent through a series of open houses.

 

“At Cornerstone Building Brands our people are the difference, dedicated to understanding and delivering on our customers’ needs by embodying a culture grounded in customer-centricity, interconnectedness and continuous improvement,” said Rose Lee, president and CEO of Cornerstone Building Brands.

 

“Manufacturing Month is the perfect opportunity for future talent to learn more about the wide range of career opportunities available within the industry, as well as the specific goals our winning team of top-tier talent is working together to achieve.”

 

MFG Day, an initiative of the Manufacturing Institute and supported by the National Association of Manufacturers, has been celebrated on the first Friday of October since 2012. This year’s celebrations come at a particularly crucial time for the future of the modern manufacturing industry as thousands of jobs remain unfilled month-to-month. According to the latest research from the Manufacturing Institute, this skills gap has led to more than 2.1 million U.S. manufacturing jobs that need to be filled by 2030.1

 

Cornerstone Building Brands is addressing this deficit by opening its doors to the next generation of manufacturing professionals. At its exterior siding facility in Jasper, Tennessee, and its windows facility in North Brunswick, New Jersey, high school students, teachers and community leaders are invited to tour the facilities and experience the product development process hands-on. Cornerstone Building Brands facility and company leadership will also be in attendance to facilitate event activities and offer insight into available career and professional development opportunities.

 

“I’m proud to be part of a team that works together safely, inclusively and with integrity to ensure our products reach the highest quality levels every time,” said John Wallace, executive vice president, operational excellence at Cornerstone Building Brands.

 

“We look forward to continuing this standard of excellence and welcoming the next generation to explore the many opportunities in an ever-evolving manufacturing industry.”

 

In addition to community events, the company is also shining a light on its network of team members across North America who are dedicated to making a positive impact on their customers and communities. At its more than 170 locations, Cornerstone Building Brands is recognizing team members throughout October by hosting team building and employee appreciation events, celebrating the work team members do every day as critical members of the manufacturing industry.

 

This year’s Manufacturing Month celebrations are just one way the company positively impacts the communities where team members live, work and play. Through Cornerstone Building Brands Cares initiatives, the company works with local partners and charitable organizations to donate building products, facilitate house builds and strengthen volunteer engagement. To date, Cornerstone Building Brands has donated more than $3.1 million in products and resources, helping to build or remodel more than 670 homes in 90 communities through its Home for Good project.

 

To learn more about Manufacturing Day at Cornerstone Building Brands, visit cornerstonebuildingbrands.com/mfgday.

 

About Cornerstone Building Brands

Cornerstone Building Brands is the largest manufacturer of exterior building products by sales for residential and low-rise non-residential buildings in North America. Headquartered in Cary, N.C., we serve residential and commercial customers across the new construction and repair and remodel markets. Our market-leading portfolio of products spans vinyl windows, vinyl siding, stone veneer, metal roofing, metal wall systems and metal accessories. Cornerstone Building Brands’ broad, multichannel distribution platform and expansive national footprint includes nearly 20,000 employees at manufacturing, distribution and office locations throughout North America. Corporate stewardship and environmental, social and governance (ESG) responsibility are embedded in our culture. We are committed to contributing positively to the communities where we live, work and play. For more information, visit us at www.cornerstonebuildingbrands.com.

1 http://www.mfgday.com/wp-content/uploads/2020/04/MFG-Day-2023-Government-Official-Toolkit.pdf

 

Contacts

Investor Relations:
Jason Uthe

SVP, Finance & Investor Relations

response@cornerstone-bb.com

 

Media Relations:
Susan Selle

Chief Marketing Officer

response@cornerstone-bb.com

Categories
Business Economics Healthcare Lifestyle Programs & Events Technology

Digital Health Solution, Dentistry.One, bridges the gap between dental and medical care for improved health and lower costs – Visit us at HLTH 2023

Booth #2450-22 (DiMe Virtual First Care Pavilion) and Booth #4950-5 (CareQuest Systemic Health Pavilion)

 

METUCHEN, N.J. — (BUSINESS WIRE) — Dentistry.One, a virtual-first dental care solution introduced by MouthWatch, LLC, will showcase at Booth #2450-22 (DiMe Virtual First Care Pavilion) and Booth #4950-5 (CareQuest Systemic Health Pavilion) during the upcoming HLTH 2023 conference in Las Vegas.

 

“It is an honor to be at HLTH 2023 alongside thousands of individuals and organizations dedicated to enhancing patient health through technology and innovation,” said Brant Herman, Founder and CEO, MouthWatch, LLC and Dentistry One LLC.

 

“We are excited to demonstrate how Dentistry.One is digitally bridging the gap that has existed for far too long between dental and medical care,” continued Herman. “We’re leveraging teledentistry technology and oral health expertise to tangibly remove barriers to improved health and lower costs, especially for patients with oral-systemic conditions.”

 

Studies have shown that with proper oral health care, patients with oral-systemic conditions, such as heart disease, diabetes, and pregnancy, experience better health outcomes and a lower cost of care. According to a study published in Science Direct, cost of care for diabetes is reduced annually by $2,840.00 per patient; heart disease, $1,090.00 per patient, and pregnancy, $2,433 per patient.

 

“With the proven oral-systemic connection and compelling data underscoring the positive impact of preventive oral healthcare, it could not be a better time to participate in HLTH 2023,” said Dr. Carolyn Brown, Chief Dental Officer at Dentistry One. “We look forward to strategizing with other innovative companies at HLTH and investors in health technology, with the goal of rapidly accelerating medical-dental integration with best-in-class virtual care and a tech stack built for tomorrow.”

 

Dentistry.One provides 24/7 access to a nationwide network of on-demand dentists and a team of Care Advisors, experts in dental hygiene. Individuals can more easily prioritize their oral health and organizations focused on patient health, such as health plans, employers, benefits brokers, and dental service organizations, can differentiate their portfolio of benefits, improve the member, patient, or employee experience, and achieve their business goals.

 

Dentistry.One virtual-first care services range from emergency care, live and asynchronous consultations for oral-systemic related conditions, pre-and-post op support, ortho consultations, surgical clearance, e-prescriptions (non-narcotic), and second opinions, to timely answers to general dental concerns that help prevent development of more serious and costly health issues.

 

Care Advisors make the patient journey seamless with personalized care coordination to in-office appointments, assistance with benefits navigation, and oral health coaching. In addition, Dentistry.One increases patient engagement in oral health through data-driven educational campaigns tailored to address specific health topics aligned with individual needs.

 

To schedule time to speak with us about Dentistry.One during HLTH 2023, please click here.

 

About MouthWatch, LLC

MouthWatch, LLC, is a leader in developing digital technology solutions that drive success for dental professionals, improve oral health care, and enhance the overall patient experience.

 

Headquartered in Metuchen, New Jersey, MouthWatch is widely known for its intraoral cameras that help engage patients in treatment planning through high quality, affordable imaging technology, and its TeleDent software that provides practices and organizations with a teledentistry option to engage patients with providers remotely.

 

MouthWatch launched Dentistry.One, a virtual-first care network that addresses the expectations of today’s modern healthcare consumers, the need for greater efficiency in healthcare, and the proven connection between good oral health and total health. Dentistry.One features on-demand dental consultations, personalized care coordination, and oral health coaching for prioritizing oral health.

 

MouthWatch hardware and software are in use at over 40,000 practices, over 30 leading Dental Service Organizations (DSOs), and over 100 dental schools. The company has been recognized three times in the Inc. 5000.

 

For more information, visit mouthwatch.com or dentistry.one.

Contacts

Media Contact:
Shifra Pfister

Marketing Operations Manager

MouthWatch, LLC & Dentistry One LLC

shifra@mouthwatch.com
609.721.3187

Categories
Business Economics Lifestyle Local News Science

Dodge Momentum Index rises 3% in September following August decline

Institutional planning drives DMI higher, while commercial planning declines

 

HAMILTON, N.J. — (BUSINESS WIRE) — The Dodge Momentum Index (DMI), issued by Dodge Construction Network, improved 3% in September to 182.5 (2000=100) from the revised August reading of 178.0. Over the month, the commercial component of the DMI fell 1%, while the institutional component increased 9%.

 

“Solid demand for data centers, life science labs and hospitals supported the uptick in nonresidential planning activity last month,” said Sarah Martin, associate director of forecasting for Dodge Construction Network. “While month-to-month trends can be volatile, year-to-date trends show an overall decrease in commercial planning, offset by more institutional projects entering the queue. If financial conditions improve in early 2024, steady planning activity should follow.”

 

Weaker office planning drove the commercial segment of the DMI down, while the acceleration in the institutional segment was supported by stronger education, notably life science buildings, and healthcare planning activity. Year over year, the DMI was 5% lower than in September 2022. The commercial segment was 12% below year-ago levels, while the institutional segment was up 12% over the same time period.

 

A total of 20 projects valued at $100 million or more entered planning in September. The largest commercial projects to enter planning included the $400 million Platform 16 office development in San Jose, California and the $230 million Waterford Millstone Data Center in Waterford, Connecticut. The largest institutional projects to enter planning included the $927 million UC San Diego Research Park in San Diego, California and phases three and four of the Kilroy Oyster Point Life Sciences Complex in San Francisco, California, valued at a total of $634 million.

 

The DMI is a monthly measure of the initial report for nonresidential building projects in planning, shown to lead construction spending for nonresidential buildings by a full year.

 

Watch Associate Director of Forecasting Sarah Martin discuss September’s DMI here.

 

About Dodge Construction Network

Dodge Construction Network leverages an unmatched offering of data, analytics, and industry-spanning relationships to generate the most powerful source of information, knowledge, insights, and connections in the commercial construction industry. The company powers four longstanding and trusted industry solutions—Dodge Data & Analytics, The Blue Book Network, Sweets, and IMS—to connect the dots across the entire commercial construction ecosystem. Together, these solutions provide clear and actionable opportunities for both small teams and enterprise firms. Purpose-built to streamline the complicated, Dodge Construction Network ensures that construction professionals have the information they need to build successful businesses and thriving communities. With over a century of industry experience, Dodge Construction Network is the catalyst for modern commercial construction.

Contacts

Amy Roepke | Dodge Construction Network | Amy.Roepke@construction.com

Categories
Business Healthcare Lifestyle Science

Sanofi and Teva announce exclusive collaboration to deliver inflammatory bowel disease treatment

  • TEV ‘574, a novel anti-TL1A therapy, is being developed to treat ulcerative colitis and Crohn’s disease
  • Collaboration supports Sanofi’s immunology strategy of exploring novel mechanisms of action for chronic inflammatory diseases
  • Collaboration leverages the innovative R&D and commercial expertise of both companies

 

PARIS & PARSIPPANY, N.J. — (BUSINESS WIRE) — Sanofi (EURONEXT: SAN and NASDAQ: SNY) and Teva Pharmaceuticals, a U.S. subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announce today a collaboration to co-develop and co-commercialize asset TEV ‘574, currently in Phase 2b clinical trials for the treatment of Ulcerative Colitis and Crohn’s Disease, two types of inflammatory bowel disease.

 

Paul Hudson

Chief Executive Officer, Sanofi

“Anti-TL1As are a promising class of therapies, and we believe that TEV ‘574 could emerge as a best-in-class option for people living with serious gastrointestinal diseases. This collaboration strengthens our commitment to advancing innovative treatment options for inflammatory conditions with a high unmet need and bolsters our goal to be an industry leader in immunology.”

 

Richard Francis

President and Chief Executive Officer, Teva

“This is a new era for Teva, and our robust, innovative pipeline is key to our Pivot to Growth strategy. This collaboration further validates the great science that Teva has to offer with our internally developed anti-TL1A. We are honored to partner with Sanofi to bring their proven capabilities, leadership, and success in the immunology and gastroenterology space together with our capabilities to optimize development and global launches.”

 

Under the terms of the new collaboration agreement, Teva will receive an upfront payment of €469 million ($500 million) and up to €940 million ($1 billion) in development and launch milestones. Each company will equally share the development costs globally and net profits and losses in major markets, with other markets subject to a royalty arrangement and Sanofi will lead the development of the Phase 3 program. Teva will lead commercialization of the product in Europe, Israel and specified other countries, and Sanofi will lead commercialization in North America, Japan, other parts of Asia and the rest of the world. The transaction will become effective after customary closing conditions are met. Initial program results are expected to be available in 2024.

 

Inflammatory bowel disease (IBD) is the term for two conditions — Crohn’s disease and ulcerative colitis – characterized by chronic inflammation of the gastrointestinal (GI) tract. Prolonged inflammation results in damage to the GI tract. The common symptoms for both conditions are persistent diarrhea, rectal bleeding, abdominal pain, fatigue, and weight loss. An estimated ~10 million people worldwide live with IBD.

 

Teva Investor Call

Teva will hold an investor call and live webcast today (Wednesday, October 4, 2023) at 8:00 a.m. ET to discuss this collaboration. To participate, please register in advance here to obtain a local or toll-free phone number and your personal pin. A live webcast of the call will be available on Teva’s website at: https://ir.tevapharm.com/Events-and-Presentations.

 

About Sanofi

We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY

 

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has been developing and producing medicines to improve people’s lives for more than a century. We are a global leader in generic and innovative medicines with a portfolio consisting of over 3,500 products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day and are served by one of the largest and most complex supply chains in the pharmaceutical industry. Along with our established presence in generics, we have significant innovative research and operations supporting our growing portfolio of innovative and biopharmaceutical products. Learn more at www.tevapharm.com.

 

Sanofi Forward-Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi’s ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that pandemics or other global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2022. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

 

Teva Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as “should,” “expect,” “anticipate,” “estimate,” “target,” “may,” “project,” “guidance,” “intend,” “plan,” “believe” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include: risks relating to our exclusive collaboration with Sanofi, including uncertainties around the effective date of the collaboration and our ability to satisfy the closing conditions related thereto; risks related to the timing of and our ability to achieve expected results for TEV-48574 (anti-TL1A), including our ability to commercialize TEV-48574 (anti-TL1A); the extent to which we will realize the anticipated financial and other benefits of the Sanofi collaboration; our ability to satisfy the conditions to receiving milestone cash payments under the Sanofi collaboration agreement; the risk that we will incur significant costs in connection with the development of TEV-48574 (anti-TL1A), which may exceed any revenue generated by TEV-48574 (anti-TL1A); risks that regulatory approvals and other requirements may delay the development and commercialization of TEV-48574 (anti-TL1A); our ability to successfully compete in the marketplace, including our ability to develop and commercialize biopharmaceutical products, competition for our innovative medicines, including AUSTEDO®, AJOVY® and COPAXONE®, our ability to achieve expected results from investments in our product pipeline, our ability to develop and commercialize additional pharmaceutical products, and the effectiveness of our patents and other measures to protect our intellectual property rights; our ability to successfully launch and execute our new Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development, and to sustain and focus our portfolio of generics medicines; our substantial indebtedness which may limit our ability to incur additional indebtedness, engage in additional transactions or make new investments, may result in a further downgrade of our credit ratings; and our inability to raise debt or borrow funds in amounts or on terms that are favorable to us; our business and operations in general, including, the impact of global economic conditions and other macroeconomic developments and the governmental and societal responses thereto, and costs and delays resulting from the extensive pharmaceutical regulation to which we are subject; compliance, regulatory and litigation matters, including failure to comply with complex legal and regulatory environments; other financial and economic risks; and other factors discussed in our Quarterly Report on Form 10-Q for the second quarter of 2023 and in our Annual Report on Form 10-K for the year ended December 31, 2022, including in the section captioned “Risk Factors.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.

 

Contacts

Sanofi Media Relations
Sally Bain | + 1 617 834 6026 | sally.bain@sanofi.com
Sandrine Guendoul | + 33 6 25 09 14 25 | sandrine.guendoul@sanofi.com
Victor Rouault | + 33 6 70 93 71 40 | victor.rouault@sanofi.com

Sanofi Investor Relations
Eva Schaefer-Jansen | + 33 7 86 80 56 39 | eva.schaefer-jansen@sanofi.com
Arnaud Delépine | + 33 6 73 69 36 93 | arnaud.delepine@sanofi.com
Corentine Driancourt | + 33 6 40 56 92 21 | corentine.driancourt@sanofi.com
Felix Lauscher | + 1 908 612 7239 | felix.lauscher@sanofi.com
Tarik Elgoutni| + 1 617 710 3587 | tarik.elgoutni@sanofi.com
Nathalie Pham | + 33 7 85 93 30 17 | nathalie.pham@sanofi.com

Teva Investor Relations
Ran Meir | (267) 468-4475

Yael Ashman | +972 (3) 914 8262

Sanjeev Sharma | (973) 524-1908

Teva Corporate Affairs
Kelley Dougherty | (973) 658-0237

Eden Klein | +972 (3) 906 2645

Categories
Business Healthcare Lifestyle Science

Additional results of POSLUMA® (Flotufolastat F 18) performance in newly diagnosed, high-risk prostate cancer patients presented at ASTRO

− Sub-group analysis from Blue Earth Diagnostics’ Phase 3 LIGHTHOUSE trial highlights POSLUMA utility to guide treatment selection and potentially avoid futile surgery –

 

 

MONROE TOWNSHIP, N.J. & OXFORD, England — (BUSINESS WIRE) — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative positron emission tomography (PET) radiopharmaceuticals, on Wednesday announced results from a sub-group analysis from the Phase 3 LIGHTHOUSE trial (NC04186819) which evaluated the safety and diagnostic performance of POSLUMA® (flotufolastat F 18) PET in men with newly diagnosed prostate cancer. Specifically, this sub-group examined the performance of flotufolastat F 18 PET in newly diagnosed, high-risk prostate cancer patients who had negative results with conventional imaging. Recently approved by the U.S. FDA, POSLUMA is indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer with suspected metastasis who are candidates for initial definitive therapy or with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level.

 

Results highlights:

  • The sensitivity and specificity of flotufolastat F 18 for the detection of pelvic lymph nodes in 174 patients who underwent surgery ranged from 24-33% and 92-96%, respectively, across 3 blinded, independent readers.
  • The detection rate for M1 lesions (lesions that have spread beyond the pelvic area) for flotufolastat F 18 in 197 patients was 14% – 25% across the 3 readers.
  • Of identified lesions, 16-25 were successfully verified as True Positive, providing a M1 Verified Detection Rate (VDR) of 8.1 – 13%, across the 3 readers.

 

“Effective initial staging of prostate cancer, particularly with regards to the detection of metastatic disease, is critical to optimal clinical management of patients,” said Phillip H. Kuo, MD, Ph.D., Departments of Medical Imaging, Medicine, and Biomedical Engineering. “The demonstrated performance of PSMA-PET imaging fits an important unmet need, given that conventional imaging techniques are limited in the information they provide. This analysis from the LIGHTHOUSE study showed that flotufolastat F 18 provides clinically useful information about the presence of both metastatic pelvic lymph nodes and M1 disease prior to surgery in patients with high-risk prostate cancer who had negative results on conventional imaging. Such information can help guide treatment selection and potentially avoid futile surgery for patients with high-risk disease.”

 

“We are pleased to present these results from the LIGHTHOUSE study to the radiation oncology community at ASTRO,” said David E. Gauden, D.Phil., Chief Executive Officer of Blue Earth Diagnostics. “POSLUMA provides physicians with high-quality diagnostic information based on its diagnostic performance even at low PSA levels, high-affinity PSMA binding and low urinary bladder activity. In a post-hoc Phase 3 analysis, as well as in preclinical and Phase 1 studies, POSLUMA demonstrated low urinary bladder activity, providing for enhanced image evaluation in the prostate and regions near the ureters for patients with prostate cancer. The product is labeled with the radioisotope fluorine-18 (18F) to leverage the high image quality of 18F-labeled PSMA PET imaging, to facilitate effective detection of disease and enable broad, readily available geographic access for patients through the manufacturing and distribution network of our commercial U.S. manufacturer and distributor, PETNET Solutions Inc, A Siemens Healthineers Company. Nationally recognized clinical oncology guidelines for prostate cancer now include POSLUMA, alongside and for all the same categories as the other currently FDA-approved PSMA PET radiopharmaceuticals.”

 

The findings were discussed in a poster Q&A session at the 2023 ASTRO Annual Meeting on October 3, 2023,“Diagnostic Performance of 18F-rhPSMA-7.3 PET in Men with Newly Diagnosed High-risk Prostate Cancer and Negative Conventional Imaging,” by Phillip H. Kuo, MD, Ph.D., Departments of Medical Imaging, Medicine, and Biomedical Engineering, University of Arizona, Tucson, Ariz. on behalf of Gary A. Ulaner, MD, Ph.D., Hoag Family Cancer Institute, Irvine, Calif. and University of Southern California, Los Angeles, Calif., for the LIGHTHOUSE Study Group. Full session details and the abstract are available in the ASTRO online program here.

 

About the study

The sub-group analysis of LIGHTHOUSE data evaluated a subgroup of patients with high/very high-risk prostate cancer who had no evidence of nodal or metastatic disease on conventional imaging. Treatment-naïve patients scheduled for radical prostatectomy (RP) plus pelvic lymph node (PLN) dissection underwent flotufolastat F 18 PET. Local readers interpreted the scans prior to RP and ahead of a blinded read by 3 central readers. If the local read indicated M1 disease, verification (biopsy, surgery, or confirmatory follow-up imaging) of PET-positive M1 lesions was attempted before treatment. The analysis evaluated flotufolastat F 18 sensitivity and specificity for detection of PLN metastases in all high/very high-risk patients with negative conventional imaging at baseline who underwent flotufolastat F 18 PET and subsequent surgery. Histopathology was used as the standard of truth (SoT). Additionally, the M1 verified detection rate (VDR; % of patients with true positive (TP) M1 lesions using histopathology or follow-up imaging as SoT out of all patients scanned) was assessed in an extended population of all patients who had flotufolastat F 18 PET, regardless of surgery.

 

The sensitivity and specificity for PLN detection among 174 men with very/high-risk PCa and negative conventional imaging ranged from 24-33% and 92-96%, respectively, across the 3 readers. M1 lesions were identified in 28-51 of the 197 patients in the extended population, giving an overall M1 detection rate of 14-26%, across the 3 readers. Of the identified lesions, 16-25 were successfully verified (predominantly using follow-up imaging as SoT) as TP, providing a M1 VDR of 8.1-13%, across the 3 readers.

 

No serious adverse events were observed in the LIGHTHOUSE study. Overall, 28 of the 356 (7.9%) patients who received flotufolastat F 18 had at least one treatment-emergent adverse event that was considered possibly related to flotufolastat F 18. The most frequently reported adverse event for patients in the LIGHTHOUSE study was injection site pain among 0.8% (3/356) of patients.

 

About Radiohybrid Prostate-Specific Membrane Antigen (rhPSMA)

Radiohybrid Prostate-Specific Membrane Antigen (rhPSMA) compounds consist of a radiohybrid (“rh”) Prostate-Specific Membrane Antigen-targeted receptor ligand which attaches to and is internalized by prostate cancer cells, and they may be radiolabeled with imaging isotopes for PET imaging, or with therapeutic isotopes for therapeutic use – providing the potential for creating a true theranostic technology. Radiohybrid technology and rhPSMA originated from the Technical University of Munich, Germany. Blue Earth Diagnostics acquired exclusive, worldwide rights to rhPSMA diagnostic imaging technology from Scintomics GmbH in 2018, and therapeutic rights in 2020, and sublicensed the therapeutic application to its sister company Blue Earth Therapeutics. Blue Earth Diagnostics received U.S. Food and Drug Administration approval for its radiohybrid PET diagnostic imaging product for use in prostate cancer in 2023. rhPSMA compounds for potential therapeutic use are investigational and have not received regulatory approval.

 

Indication and Important Safety Information About POSLUMA

 

INDICATION

POSLUMA® (flotufolastat F 18) injection is indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer

  • with suspected metastasis who are candidates for initial definitive therapy
  • with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level

 

IMPORTANT SAFETY INFORMATION

  • Image interpretation errors can occur with POSLUMA PET. A negative image does not rule out the presence of prostate cancer and a positive image does not confirm the presence of prostate cancer. The performance of POSLUMA for imaging metastatic pelvic lymph nodes in patients prior to initial definitive therapy seems to be affected by serum PSA levels and risk grouping. The performance of POSLUMA for imaging patients with biochemical evidence of recurrence of prostate cancer seems to be affected by serum PSA levels. Flotufolastat F 18 uptake is not specific for prostate cancer and may occur in other types of cancer, in non-malignant processes, and in normal tissues. Clinical correlation, which may include histopathological evaluation, is recommended.
  • Risk of Image Misinterpretation in Patients with Suspected Prostate Cancer Recurrence: The interpretation of POSLUMA PET may differ depending on imaging readers, particularly in the prostate/prostate bed region. Because of the associated risk of false positive interpretation, consider multidisciplinary consultation and histopathological confirmation when clinical decision-making hinges on flotufolastat F 18 uptake only in the prostate/prostate bed region or only on uptake interpreted as borderline.
  • POSLUMA use contributes to a patient’s overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk for cancer. Advise patients to hydrate before and after administration and to void frequently after administration. Ensure safe handling to minimize radiation exposure to the patient and health care providers.
  • The adverse reactions reported in ≥0.4% of patients in clinical studies were diarrhea, blood pressure increase and injection site pain.
  • Drug Interactions: androgen deprivation therapy (ADT) and other therapies targeting the androgen pathway, such as androgen receptor antagonists, may result in changes in uptake of flotufolastat F 18 in prostate cancer. The effect of these therapies on performance of POSLUMA PET has not been established.

 

To report suspected adverse reactions to POSLUMA, call 1-844-POSLUMA (1-844-767-5862) or contact FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Full POSLUMA prescribing information is available at www.posluma.com/prescribing-information.pdf.

 

About Blue Earth Diagnostics

Blue Earth Diagnostics, an indirect subsidiary of Bracco Imaging S.p.A., is a growing international molecular imaging company focused on delivering innovative, well-differentiated diagnostic solutions that inform patient care. Formed in 2014, the Company’s success is driven by its management expertise and supported by a demonstrated track record of rapid development and commercialization of positron emission tomography (PET) radiopharmaceuticals. Blue Earth Diagnostics’ expanding oncology portfolio encompasses a variety of disease states, including prostate cancer and neuro-oncology. Blue Earth Diagnostics is committed to the timely development and commercialization of precision radiopharmaceuticals for potential use in imaging and therapy. For more information, please visit: www.blueearthdiagnostics.com.

 

About Bracco Imaging

Bracco Imaging S.p.A., part of the Bracco Group, is a world-leading diagnostic imaging provider. Headquartered in Milan, Italy, Bracco Imaging develops, manufactures and markets diagnostic imaging agents and solutions. It offers a product and solution portfolio for all key diagnostic imaging modalities: X-ray imaging (including Computed Tomography-CT, Interventional Radiology, and Cardiac Catheterization), Magnetic Resonance Imaging (MRI), Contrast Enhanced Ultrasound (CEUS), and Nuclear Medicine through radioactive tracers and novel PET imaging agents to inform clinical management and guide care for cancer patients in areas of unmet medical need. Our continually evolving portfolio is completed by a range of medical devices, advanced administration systems and dose-management software. In 2019 Bracco Imaging enriched its product portfolio by expanding the range of oncology nuclear imaging solutions in the urology segment and other specialties with the acquisition of Blue Earth Diagnostics. In 2021, Bracco Imaging established Blue Earth Therapeutics as a separate, cutting-edge biotechnology vehicle to develop radiopharmaceutical therapies. Visit: www.braccoimaging.com.

Contacts

For Blue Earth Diagnostics (U.S.)
Priscilla Harlan

Vice President, Corporate Communications

(M) (781) 799-7917

priscilla.harlan@blueearthdx.com

For Blue Earth Diagnostics (UK)
Clare Gidley

Associate Director Marketing and Communications

Tel: +44 (0) 7917 536939

clare.gidley@blueearthdx.com

Media
Sam Brown Inc.

Mike Beyer

(M) (312) 961-2502

mikebeyer@sambrown.com

Categories
Business Entertainment News Lifestyle Regulations & Security Sports & Gaming

LA Kings announce Mercury Insurance as team’s first-ever Jersey patch partner and continue more than decade-long historic partnership

Multi-Year Renewal Agreement Continues Mercury’s Status as the NHL Team’s Official Partner and Builds on 16 Consecutive Years of Successful Collaboration and Positive Community Impacts Made Across Southern California

 

LOS ANGELES — (BUSINESS WIRE) — Mercury Insurance (NYSE: MCY) and National Hockey League (NHL) franchise, the LA Kings, are proud to announce a landmark, expanded renewal agreement.

 

As part of the expansive multi-year partnership, brokered by AEG Global Partnerships, Mercury will continue as an official partner of the LA Kings in addition to becoming the team’s first-ever jersey patch partner.

 

This groundbreaking agreement extends a relationship that began in 2008 for another exciting new chapter and marks a significant milestone for the insurance company as its longest running partnership to date. This is also Mercury’s first-ever jersey sponsorship, underscoring the company’s commitment to Los Angeles and the importance of hockey across the Southern California market.

 

Beginning with the upcoming 2023-24 NHL season, Mercury’s logo will be featured on the team’s on-ice home jerseys for all pre-season, regular season and playoff games taking place at Crypto.com Arena. As the official jersey partner of the LA Kings, fans will get their first look at the new jerseys with the new Mercury patch beginning with the team’s first two pre-season home games on Tuesday, October 3 when the Kings host the Anaheim Ducks at Crypto.com Arena, and Saturday, October 7 when the Kings take on the Vegas Golden Knights. This will be followed by the official debut at the team’s regular season opener on Wednesday, October 11, when the Kings host the Colorado Avalanche. Both pre-season games will be broadcast on Bally Sports SoCal and the regular season opener will be broadcast live on national television from Crypto.com Arena on TNT and is set to begin at 7:00 p.m. (PDT).

 

“We’re extremely excited and honored to be chosen as the first jersey patch partner in the team’s history,” said Erik Thompson, vice president and chief marketing officer at Mercury Insurance. “Both organizations were ‘born and raised’ in Los Angeles and we share a deep commitment to the City of Angels and the amazing people that live here. Mercury and the Kings are truly part of the fabric of Los Angeles, and nowhere is this better illustrated than on the jerseys of LA’s hockey heroes.”

 

Now in the 16th consecutive season of partnership, this expanded agreement represents two deeply rooted, Southern California-based organizations furthering their relationship for the benefit of the local fans and policyholders they both represent and serve in the region. Much like the LA Kings who played their first season in LA in 1967, Mercury also has more than 60 years of experience providing exceptional service to the Southern California market and its residents. Founded in 1961 and headquartered in Los Angeles, Mercury offers a wide variety of insurance products, including auto, home, personal liability (umbrella) business, commercial, and mechanical breakdown.

 

For close to two decades, Mercury and the LA Kings have forged an extraordinary partnership that has greatly enhanced the fan experience and helped create countless memorable moments for thousands of Angelenos. As an example, Mercury’s presenting sponsorship of the “My First Game” program brought Make A Wish youth and their families to Kings games and featured heartwarming videos of Kings players’ first experiences with the sport of hockey. Additionally, Mercury’s unique activations on game days coupled with its ongoing sponsorship of LA Kings’ community-focused initiatives have deeply enriched the fan experience and continue to help make a positive community impact all year round.

 

Going forward, the partnership will continue to incorporate significant community and fan-focused touchpoints including engaging surprise and delight activations. Among the new in-arena promotions will be “Where’s Bailey?” an augmented reality, first-of-its-kind experience that will challenge fans to search for team mascot Bailey throughout the arena and amongst some of LA’s most iconic landmarks. Everyone who finds Bailey will be entered to win a Kings prize package that includes an authentic jersey and autographed memorabilia.

 

The two organizations will also partner with LA Kings superstar, Kevin Fiala, to celebrate and honor local community heroes who are making significant impacts in their local communities. Each honoree will be inducted into the Hockeywood Community Walk of Fame art installation the two organizations are creating at Toyota Sports Performance Center in El Segundo, California. Honorees will have the chance to meet with Fiala, be integrated into the art installation and be celebrated in-arena on the videoboard, in addition to receiving a Kings jersey, tickets to a game, and an American Express gift card to help them continue their very important work.

 

“Mercury Insurance has become both a trusted and highly valued partner of our team over the years and we are honored to be making history as we welcome them as our very first jersey partner,” said LA Kings President and Hall of Famer Luc Robitaille. “Together we have grown, evolved, and most importantly given back to the diverse communities of people who support us and help make our organizations great. We look forward to creating even more cherished memories for our fans as our players step out on the ice for the very first time this season wearing the Mercury brand with pride.”

 

The long-term partnership between the LA Kings and Mercury is also highlighted by many significant milestones achieved together over the years and is testament to the strength of the growing relationship. In 2012, the Kings took home their very first Stanley Cup while Mercury celebrated its 50th anniversary, two momentous occasions the partners had the privilege of enjoying alongside each other. Just two years later in 2014, the Kings won their second Stanley Cup, followed by the team’s 50th anniversary celebrated in 2017 – additional historic moments that Mercury was a part of and helped make possible.

 

“We are extremely proud to expand this longstanding and meaningful partnership which is committed first and foremost to the fans and community. We look forward to the continued positive impact for many more years to come with our great friends at Mercury,” said Nick Baker, COO of AEG Global Partnerships.

 

ABOUT MERCURY INSURANCE

Mercury Insurance (NYSE: MCY) is a multiple-line insurance carrier predominantly offering personal auto, homeowners and renters insurance through a network of independent agents in Arizona, California, Georgia, Illinois, Nevada, New Jersey, New York, Oklahoma, Texas and Virginia, as well as auto insurance in Florida. Mercury writes other lines of insurance in various states, including commercial, business owners and business auto, landlord, home-sharing, ride-hailing and mechanical protection insurance.

 

Since 1962, Mercury has provided customers with tremendous value for their insurance dollar by pairing ultracompetitive rates with excellent customer service. Mercury has earned “A” ratings from A.M. Best and Fitch, as well as “Best Auto Insurance Company” designations from Forbes and Insure.com. For more information visit www.MercuryInsurance.com or follow the company on Twitter or Facebook.

 

ABOUT AEG

Headquartered in Los Angeles, California, AEG is the world’s leading sports and live entertainment company. The company operates in the following business segments: Facilities, which through its affiliation with ASM Global, owns, manages or consults with more than 350 preeminent arenas, stadiums, convention centers and performing arts venues around the world; Music through AEG Presents, which is dedicated to all aspects of live contemporary music performances, including producing and promoting global and regional concert tours, music and special events and world-renowned festivals such as the Coachella Valley Music and Arts Festival; Real Estate, which develops world-class venues, as well as major sports and entertainment districts like Crypto.com Arena and L.A. LIVE, Mercedes Platz in Berlin and The O2 in London; Sports, as the world’s largest operator of high-profile sporting events and sports franchises including the LA Kings, LA Galaxy and Eisbären Berlin; and Global Partnerships, which oversees worldwide sales and servicing of sponsorships including naming rights, premium seating and other strategic partnerships. Through its worldwide network of venues, portfolio of powerful sports and music brands and its integrated entertainment districts, AEG entertains more than 160 million guests annually. More information about AEG can be found at www.aegworldwide.com.

Contacts

AEG GLOBAL PARTNERSHIPS
Shannon Donnelly

Shannon.Donnelly@beckmedia.com

Categories
Business Culture Healthcare Lifestyle

Inspira Health unveils Inspira Medical Center Mannington

The integration of Salem Medical Center, an affiliate of Inspira Health is now complete, marking the health system’s expansion with a fourth hospital in South Jersey by rebranding as IMC Mannington

 

SALEM, N.J. — (BUSINESS WIRE) — Inspira Health announced that the integration Salem Medical Center, an affiliate of Inspira Health, into the health system is complete, as of Oct. 1.

 

The hospital has been rebranded as Inspira Medical Center (IMC) Mannington, effective immediately. Services at IMC Mannington include Bariatric; Behavioral and Mental Health; Cardiology; Emergency; Gastroenterology; Orthopedics; Surgical Services; Urology; and Wound Care.

 

“The finalization of this integration marks a significant milestone for our entire health system and community as Inspira Medical Center Mannington officially becomes part of the Inspira Health family,” said Amy Mansue, President and Chief Executive Officer at Inspira Health.

 

“Our combined expertise and dedication will enable us to deliver high-quality patient care and empower healthier communities as one collective team.”

 

For more than 70 years, Inspira has been steadfast in its commitment to providing safe, high-quality care to the residents of Salem County. IMC Mannington represents a seamless extension of this legacy, dedicated to offering the latest medical innovation and evidence-based care that helps each patient achieve the best possible health outcome.

 

“This integration stands firmly on the pillars of our shared mission, vision and values,” said Lydia Stockman, RN, MHA, FACHE, Senior Vice President and Chief Administrative Officer, Inspira Medical Centers. “Last December, we began the integration of Salem into our health system and over that time, we’ve gained a better understanding of the needs of the staff at Salem and the community in which they serve. With this transition, our medical staff and health care practitioners are equipped to enhance the quality, safety and patient experience to all those we serve.”

 

“With Inspira Medical Center Mannington, we stand on the threshold of an exciting new era of health care in the region,” said Warren E. Moore, FACHE, Executive Vice President, Chief Operating Officer at Inspira Health. “Together, we will redefine the standard of excellence in health care delivery for our neighbors today and for generations to come.”

 

For more information about Inspira Medical Center Mannington, please visit https://www.inspirahealthnetwork.org/.

 

About Inspira Health

Inspira Health is a charitable nonprofit health care organization and a regional leader in physician training, with approximately 277 medical residents and fellows in 15 nationally accredited programs at its hospitals in Elmer, Mullica Hill and Vineland.

 

The system traces its roots to 1899 and comprises four medical centers, two comprehensive cancer centers, eight multi-specialty health centers, and locations throughout South Jersey. These include urgent care; outpatient imaging and rehabilitation; sleep medicine labs; cardiac testing facilities; behavioral health, digestive health and wound care centers; home care and hospice; and more than 35 primary and specialty physician practices in Gloucester, Cumberland, Salem, Camden and Atlantic counties. Additionally, Inspira EMS services six South Jersey counties.

 

Inspira’s 1,200-member medical staff and more than 7,000 employees provide an unwavering commitment to delivering a superior patient experience at every point of the journey. Technology and innovation investments provide a robust provider directory and a range of services, including online scheduling and virtual visits for both primary and specialty care providers. With a commitment to multi-channel digital access, Inspira is able to meet consumer demand for self-service and personalized care options.

 

Accredited by DNV Healthcare and committed to the principles of high reliability, Inspira Health is focused on clinical excellence and patient safety. For more information about Inspira Health, visit http://www.InspiraHealthNetwork.org or call 1-800-INSPIRA.

 

Contacts

Red Thread PR on behalf of Inspira Health

inspirapr@redthreadpr.com

Categories
Art & Life Culture Healthcare Lifestyle Programs & Events Science

Electeds to join Iris House in celebrating new location

Longtime HIV/AIDS service organization for women hosts White House Lawn Party with relocation to expanding Plainfield, NJ site

 

PLAINFIELD, N.J. — (BUSINESS WIRE) — Iris House, an organization focused on the needs of women living with HIV/AIDS in New York City and the greater New York/New Jersey area, is hosting – along with its affiliate organization AIDS Healthcare Foundation (AHF) – a ‘White House Garden Party’ on Wednesday, Oct. 4 to celebrate its new home in Plainfield, New Jersey.

 

Iris House will mark its 30th anniversary later this month with another celebration on Oct. 19.

 

WHAT:

‘White House Lawn Party’ celebrating Iris House’s new Plainfield, NJ location

WHEN:

Wednesday, October 4, 2023

TIME:

4:30 pm – 6:30 pm ET

WHERE:

209 West 8th Street, Plainfield, NJ 07060

WHO:

  • Ingrid Floyd, Executive Director, Iris House
  • Hon. Adrian O. Mapp, Mayor of Plainfield
  • Hon. Charles McRae, Plainfield City Council President
  • Hon. Rebecca Williams, Union County Commissioner
  • Donna Tempesta, AHF Northern Bureau Chief and VP of Finance
  • Marlene LaLota, AHF Senior Regional Director, Northern Region, and
  • Hon. Linda. S. Carter, NJ Assemblywoman (District 22) with presentation of an Iris House Resolution

 

“Our ‘White House’ moniker for both this party and our new building refers to the impressive regal white structure in Plainfield that now is home to Iris House staff and many of our services. In our work in New Jersey, we have a particular focus on youth and young adults, which we will be able to expand on at this new site in addition to continue our services to and for women living with HIV,” said Ingrid Floyd, Iris House Executive Director.

 

“We are grateful to share this special day— and this space—with many dedicated elected officials and supporters as well as with AHF, our partner in fighting AIDS and providing HIV care and services.”

 

The Plainfield site eventually will house a new, state-of-the-art AHF Healthcare Center providing cutting-edge medical care and services to patients regardless of ability to pay and will also feature an AHF Pharmacy Access Center.

 

ABOUT:

Iris House Established in 1993, Iris House focuses on the needs of women living with HIV or AIDS in New York City and the greater New York/New Jersey area. It affiliated with AHF in July 2019.

 

AIDS Healthcare Foundation (AHF), the world’s largest HIV/AIDS healthcare organization, provides cutting-edge medicine and advocacy to more than 1.9 million individuals across 45 countries, including the U.S. and in Africa, Latin America/Caribbean, the Asia/Pacific Region, and Eastern Europe. To learn more about AHF, visit us online at AIDShealth.org, find us on Facebook, follow us on Instagram, Twitter, and TikTok, and subscribe to our AHFter Hours podcast.

Contacts

Rasheed Gonga, AHF Advocacy, Legislative Affairs & Community Engagement

(201) 241-0927

Rasheed.gonga@ahf.org